Apotex stock began trading on the Toronto Stock Exchange on June 10, 2026, as the company moved ahead with an initial public offering expected to raise $1.3 billion. The listing gives the Toronto-based drugmaker a public market valuation story tied to one of the largest IPOs in TSX history by total proceeds raised.
Jeff Watson, the president and CEO of Apotex, called the debut an important milestone and said the company was proud to begin trading on the TSX. For shareholders and prospective investors, the key development is not just the listing itself but the scale: this is the largest life sciences IPO in TSX history by total proceeds raised.
TSX APTX starts trading
TSX: APTX opened on June 10 after Apotex Health Corp. began trading under that symbol on the exchange. The company’s IPO was expected to raise $1.3 billion, a size that places it among the largest offerings ever listed in Toronto and the biggest in the life sciences category on the exchange.
Loui Anastasopoulos, the CEO of Toronto Stock Exchange, said: “We are extremely proud to welcome Apotex, a Canadian company competing on the global stage, to Toronto Stock Exchange. Its debut is a testament to the strength of the Canadian capital markets and shows the potential of the life sciences sector to the world” — and that framing puts the deal in the context of an exchange trying to show depth in a sector that has had 110 listed life sciences companies as of May 31, 2026, with a combined market capitalization of $26 billion.
Watson and McKenzie open trading
Thursday, June 11, at 9:30 a.m. ET was set for Jeff Watson and John McKenzie to open trading at TSX’s market open ceremony. That sequence matters because the company was not just listing; it was being folded into an exchange ritual that signals how the market is presenting the deal to investors.
Watson said: “This listing reflects the strength of our global business and the dedication of our teams who are committed to improving access to affordable, high-quality medicines for patients around the world.” He also said: “We are proud to be the leading Canadian-based health company, and excited for the opportunities ahead as we continue to invest in innovation, expand our reach, and deliver long-term value for patients and shareholders alike.”
TSX life sciences scale
110 life sciences companies were listed on both TSX and TSX Venture Exchange as of May 31, 2026, and their combined market capitalization reached $26 billion. Against that backdrop, Apotex enters as the largest Canadian-based pharmaceutical company, headquartered in Toronto with regional offices in the United States, Mexico and India.
$1.3 billion in expected IPO proceeds is the number that now defines the listing for investors assessing supply, demand and size in one of Toronto’s most visible capital-markets launches. For readers tracking the sector, the practical takeaway is that Apotex stock is now part of a public market that TSX is actively using to showcase Canadian health-care scale, with June 11’s opening ceremony serving as the next visible step in the float’s rollout.
